BMC Gastroenterology (Aug 2010)

Constitutive activation of glycogen synthase kinase-3β correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer

  • Cho Yu,
  • Kim Ji,
  • Yoon Jiyeon,
  • Cho Sung,
  • Ko Young,
  • Park Jong-Wan,
  • Lee Hye,
  • Lee Hee,
  • Kim Woo,
  • Lee Byung

DOI
https://doi.org/10.1186/1471-230X-10-91
Journal volume & issue
Vol. 10, no. 1
p. 91

Abstract

Read online

Abstract Background Aberrant regulation of glycogen synthase kinase-3β (GSK-3β) has been implicated in several human cancers; however, it has not been reported in the gastric cancer tissues to date. The present study was performed to determine the expression status of active form of GSK-3β phosphorylated at Tyr216 (pGSK-3β) and its relationship with other tumor-associated proteins in human gastric cancers. Methods Immunohistochemistry was performed on tissue array slides containing 281 human gastric carcinoma specimens. In addition, gastric cancer cells were cultured and treated with a GSK-3β inhibitor lithium chloride (LiCl) for immunoblot analysis. Results We found that pGSK-3β was expressed in 129 (46%) of 281 cases examined, and was higher in the early-stages of pathologic tumor-node-metastasis (P P P P P Conclusions GSK-3β activation was frequently observed in early-stage gastric carcinoma and was significantly correlated with better prognosis. Thus, these findings suggest that GSK-3β activation is a useful prognostic marker for the early-stage gastric cancer.